Short answer
ACTUATE THERAPEUTICS, INC. (ACTU) filed an 8-K current report with the SEC on May 6, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). Martin H. Huber, MD appointed Class III director, expanding Board from seven to eight members.
ACTUATE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Martin H. Huber, MD appointed Class III director, expanding Board from seven to eight members
- Huber joins Nominating and Corporate Governance Committee, adding senior oncology development expertise
- Initial grant: non-statutory options for 30,000 shares, vesting over three years
- Annual director retainer $44,000 plus quarterly R&D consulting fee of $3,000
- Former Mersana CEO and current Syndax Pharmaceuticals director, strengthening industry and clinical-development credentials
Item 8.01 · Other Events
- Section 8.01 contains only standard Form 8-K liability and incorporation-by-reference language
- No substantive corporate event or investor-impacting disclosure appears in the provided text
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACTUATE THERAPEUTICS, INC. 8-K filings
Get the next ACTU 8-K as it lands
Follow ACTU for push alerts, or ask the research agent what this filing means.